Levofloxacino Cinfa (Levofloxacin)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. Inhibiting these targets prevents bacterial cells from duplicating their genetic material, leading to bacterial death and resolution of the infection.

The dosage of Levofloxacino Cinfa is determined by the prescribing clinician based on the infection type, severity, patient age, renal function, and other clinical factors. Patients should follow the exact regimen provided by their health‑care professional.

Safety data for levofloxacin in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used when clearly needed and after a risk‑benefit assessment by the prescriber. Breastfeeding mothers should consult their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Levofloxacin is a third‑generation fluoroquinolone with broad‑spectrum activity against Gram‑negative and Gram‑positive bacteria. Compared with older agents like ciprofloxacin, levofloxacin offers once‑daily dosing for many infections and a slightly improved safety profile, though class‑related warnings such as tendon risk remain.

Levofloxacino Cinfa should be stored at ambient temperature, below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Levofloxacino Cinfa is taken orally, usually with a full glass of water. It can be taken with or without food, but antacids containing aluminum or magnesium should be spaced at least two hours apart to avoid reduced absorption.

Serious risks include tendon rupture (especially in the Achilles), QT interval prolongation leading to cardiac arrhythmias, severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome, and central nervous system effects like seizures. Patients should seek immediate medical attention if these events occur.

Levofloxacino Cinfa is contraindicated in patients with a known hypersensitivity to levofloxacin or other fluoroquinolones. It should also be avoided in individuals with a history of tendon disorders related to fluoroquinolone use, and in patients receiving concomitant medications that may cause dangerous QT prolongation.